Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

CLINICAL CHARACTERISTICS OF MATRIX METALLOPROTEINASES 2, 7, 9 AND THEIR TISSUE INHIBITORS 1 AND 2 TYPE IN THE BLOOD SERUM OF PATIENTS WITH CANCER ENDOMETRY

DOI: https://doi.org/10.29296/25877313-2018-05-07
Download full text PDF
Issue: 
5
Year: 
2018

E.S. Gershtein Dr.Sc. (Biol.), Professor, Laboratory of Clinical Biochemistry, N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russian Federation (Moscow) S.V. Mushtenko Post-graduate Student, Department of Oncology, A.I. Evdokimov Moscow State University of Medicine and Dentistry I.V. Tereshkina Ph.D. (Med.), Department of Clinical Biochemistry and Laboratory Diagnostics, A.I. Evdokimov Moscow State University of Medicine and Dentistry D.N. Kushlinsky Ph.D. (Med.), Oncogynecologist, National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician RAS V.I. Kulakov Ministry of Health of Russian Federation (Moscow) V.D. Ermilova Ph.D. (Med.), Leading Research Scientist, N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russian Federation (Moscow) N.E. Levchenko Dr.Sci. (Med.), Professor, Head of the Department of Gynecology, N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russian Federation (Moscow) L.V. Adamyan Dr.Sci. (Med.), Professor, Academician of Russian Academy of Sciences, Deputy Director for Research, National Medical Research Center of Obstetrics, Gynecology and Perinatology Academician RAS V.I. Kulakov Ministry of Health of Russian Federation (Moscow) N.E. Kushlinskii Dr.Sci. (Med.), Professor, Member-Corresponding RAS, Head of the Laboratory of Clinical Biochemistry, N.N. Blokhin National Medical Research Center Oncology of Health of Russian Federation (Moscow)

A comparative study of the content of MMP-2, 7, 9 and their tissue inhibitors TIMP-1 and TIMP-2 in the serum of 94 patients with cancer, 28 polyps, 25 endometrial hyperplasia and 77 healthy donors is presented. A significant increase in MMP-7 and TIMP-2 levels in both cancer and benign changes in the endometrium has been shown. A significant relationship between the levels of the investigated markers with prevalence rates, the histological structure and the degree of differentiation of endometrial cancer has not been revealed. We have to state that MMP and TIMP included in the study can not be considered as potential diagnostic markers of endometrial cancer. At the same time, such a marker as MMP-7 can be useful for monitoring patients, assessing the prognosis of the disease and sensitivity to targeted therapy, especially since significant serological markers have not yet been found in endometrial carcinoma.
Keywords: 
MMP-2
7
9
TIMP-1
TIMP-2
endometrial cancer

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions // Biochim. Biophys. Acta. 2010. V. 1803. № 1. P. 103–120.
  2. Määttä M., Soini Y., Liakka A., Autio-Harmainen H. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation // Am. J. Clin. Pathol. 2000. V. 114. № 3. P. 402–411.
  3. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, biochemistry // Circ. Res. 2003. V. 92. № 8. P. 827–839.
  4. Gershtein E.S., Kushlinskii N.E. Clinical prospects of research of tumor-associated proteases and their tissue inhibitors in cancer patients. Bulletin of the Russian Academy of Medical Sciences. 2013. № 5. P. 16–27.
  5. Ueno H., Yamashita K., Azumano I., Inoue M., Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas // Int. J. Cancer. 1999. V. 84. № 5. P. 470–477.
  6. Inoue Y., Abe K., Obata K., Yoshioka T., Ohmura G., Doh K., Yamamoto K., Hoshiai H., Noda K. Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type-IV collagen in endometrial carcinoma // J. Obstet. Gynaecol. Res. 1997. V. 23. № 2. P. 139–145.
  7. Graesslin O., Cortez A., Fauvet R., Lorenzato M., Birembaut P., Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinicalpathological correlation study // Ann. Oncol. 2006. V. 17. № 4. P. 637–645.
  8. Tunuguntla R., Ripley D., Sang Q.X., Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer // Gynecol. Oncol. 2003. V. 89. № 3. P. 453–459.
  9. Erdemoglu E., Güney M., Karahan N., Mungan T. Immunohistochemical expression of MMP-2, MMP-9 and COX-2 in Stage IA malignant polyps of the endometrium // Eur. J. Gynaecol. Oncol. 2008. V. 29. № 5. P. 444–449.
  10. Shaco-Levy R., Sharabi S., Benharroch D., Piura B., SionVardy N. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium // Eur. J. Obstet. Gynecol. Reprod. Biol. 2008. V. 139. № 2. P. 226–232.
  11. Weigel M.T., Kramer J., Schem C., Wenners A., Alkatout I., Jonat W., Maass N., Mundhenke C. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma // Eur. J. Obst. Gynecol. Reprod. Biol. 2012. V 160. № 1. P. 74–78.
  12. Osteen K.G., Yeaman G.R., Bruner-Tran K.L. Matrix metalloproteinases and endometriosis. Seminars in reproductive medicine. 2003. V. 21. № 2. P. 155–164.
  13. Aglund K., Rauvala M., Puistola U., Angstrom T., Turpeenniemi-Hujanen T., Zackrisson B., Stendahl U. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage // Gynecol. Oncol. 2004. V. 94. № 3. P. 699–704.
  14. Graesslin O., Cortez A., Uzan C., Birembaut P., Quereux C., Darai E. Endometrial tumor invasiveness is related to
  15. metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions // Int. J. Gynecol. Cancer. 2006. V. 16. № 5. P. 1911–1917.
  16. Puljiz M., Puljiz Z., Vucemilo T., Ramic S., Knezevic F., Culo B., Alvir I., Tomica D., Danolic D. Prognostic significance of matrix metalloproteinases 2 and 9 in endometrial cancer // Coll. Antropol. 2012. V. 36. № 4. P. 1367–1372.
  17. Misugi F., Sumi T., Okamoto E., Nobeyama H., Hattori K., Yoshida H., Matsumoto Y., Yasui T., Honda K., Ishiko O. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis // Int. J. Mol. Med. 2005. V. 16. № 4. P. 541– 546.
  18. Mahecha A.M., Wang H. The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and -9 in angiogenesis, metastasis, and prognosis of endometrial cancer // Onco. Targets. Ther. 2017. V. 10. P. 4617–4624.
  19. Adamiak A., Postawski K., Semczuk A., Rechberger T., Jakowicki J.A. Prognostic value of serum MMP-2 level in uterine cancer affected women // Ginekol. Pol. 2000. V. 71. № 9. P. 1198–1201.
  20. Honkavuori M., Talvensaari-Mattila A., Puistola U., Turpeenniemi-Hujanen T., Santala M. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma // Anticancer Res. 2008. V. 28. № 5A. P. 2715–2719.
  21. Yabushita H., Iwasaki K., Kanyama K., Obayashi Y., Zhuo L., Itano N., Kimata K., Wakatsuki A. Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)- Hyaluronan Complex in Endometrial Cancer // Obstet. Gynecol. Int. 2011. ID 739150.
  22. Cymbaluk-Ploska A., Chudecka-Glaz A., Pius-Sadowska E., Sompolska-Rzechula A., Chudecka K., Bulsa M., Machalinski B., Menkiszak J. Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer // Dis. Markers. 2017. ID 6589262.
  23. Talvensaari-Mattila A., Santala M., Soini Y., Turpeenniemi Hujanen T. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma // Anticancer Res. 2005. V. 25. № 6B. P. 4101–4105.
  24. Yuan Y., Shen N., Yang S.Y., Zhao L., Guan Y.M. Extracellular matrix metalloproteinase inducer and matrix metalloproteinase- 2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer // Oncol. Lett. 2015. V. 10. № 1. P. 342–348.